Ask AI
VAYHIT2
VAYHIT2: Phase III Trial of Eltrombopag ± Ianalumab, an Anti-BAFF Receptor Monoclonal Antibody, as Second-line Therapy for Primary ITP

Released: December 12, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: December 12, 2025